MedTrace Logo

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00418704 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-10-01

No results posted yet for this study

Summary

The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Tarceva (150 mg) is a pill you take once a day -- every day

DRUG

taxotere

Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Chugai Pharma USA

    collaborator INDUSTRY

  • Groupe Francais De Pneumo-Cancerologie

    lead OTHER

Principal Investigators

  • Hervé LECAER, Doctor · Groupe Francais De Pneumo-Cancerologie

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-06-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418704 on ClinicalTrials.gov